RIGEL PHARMACEUTICALS INC — Director's Dealing 2024

Nov 27, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2024-11-25

Reporting Person: Santos David A (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-11-25	Employee Stock Option (right to buy)	$18.7	A	8000	Acquired	2033-01-26	Common Stock (8000)	Direct

Footnotes

F1: The Reporting Person was granted a stock option with a performance-based condition with respect to 8,000 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met.

F2: The option was fully vested on November 25, 2024, the date the determination was made that the performance metric had been met.